A case of fatal ephedra intake associated with lipofuscin accumulation, caspase activation and cleavage of myofibrillary proteins by Chen‐scarabelli, Carol et al.
www.elsevier.com/locate/heafaiThe European Journal of HeartCase report
A case of fatal ephedra intake associated with lipofuscin accumulation,
caspase activation and cleavage of myofibrillary proteins
Carol Chen-Scarabellia,*, Siân E. Hughesb, Giorgio Landonb, Peter Rowleyb, Zuhair Allebbanc,
Noel Lawsond, Louis Saravolatze, Julius Gardinc, David Latchmanf, Tiziano M. Scarabellic
aDivision of Cardiology, VA Medical Center, University of Michigan, Ann Arbor, MI, USA
bDepartment of Histopathology, Royal Free and University College Medical School, University College London, London, UK
cDivisions of Cardiology, St John Hospital, Wayne State University, Detroit, MI, USA
dDivisions of Pathology, St John Hospital, Wayne State University, Detroit, MI, USA
eDivisions of Internal Medicine, St John Hospital, Wayne State University, Detroit, MI, USA
fInstitute of Child Health, University College London, London, UK
Received 22 April 2004; received in revised form 17 July 2004; accepted 20 September 2004Abstract
Ephedra, a herb reported to suppress appetite and stimulate the sympathetic nervous system as well as cardiac performance, has recently
been related to several adverse events, including seizure, stroke, hypertension, myocardial infarction, and sudden death. Here, we describe the
case of a 45-year-old woman who died of cardiovascular collapse while taking ephedra. Tissue analysis revealed non-specific degenerative
alterations in the myocardium (lipofuscin accumulation, basophilic degeneration and vacuolation of myocytes, as well as myofibrillary loss),
associated with myocyte apoptosis, caspase activation, and extensive cleavage of miofibrillary proteins a-actin, a-actinin, and cardiac
troponin T. Healthcare professionals are therefore urged to warn their patients about the risk of serious adverse effects, which may follow
ephedra intake.
D 2004 European Society of Cardiology. Published by Elsevier B.V.
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ephedrine, sida cordifolia, and epitoninQ, has been used in
China for thousands of years to treat asthma and other
respiratory disorders [1–3]. This herb has been reported to
stimulate the sympathetic nervous system and the heart, and
suppress appetite. The reported effects have resulted in wide
marketing of this substance in dietary supplements for
weight loss, as well as for enhanced athletic performance.
However, supplements containing ephedra or its alkaloid
derivative, ephedrine, have been linked to serious adverse
events, including seizure, stroke, and cardiovascular effects,
ranging from hypertension and myocardial infarction to
sudden death [1–4].1388-9842/$ - see front matter D 2004 European Society of Cardiology. Publishe
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We report a case of a 45-year-old woman who died of
cardiovascular collapse while taking ephedra.
A 45-year-old woman was admitted to the hospital with
sudden cardiovascular collapse after taking aspirin, while
using Xenadrin diet supplements. According to the emer-
gency responder report, the patient complained of a headache
and took two aspirin tablets. She subsequently vomited and
lost consciousness. Emergency medical care was summoned
and the patient, found in ventricular fibrillation and apneic,
was resuscitated and intubated on the scene, before being
transported to the hospital. Her medical history was
significant for migraines, a lump in the breast without
medical follow-up, and dermatitis. Review of her medica-
tions revealed use of Xenadrin diet pills (see Table 1) [5],
aspirin, Prozac, and Nicotrol inhaler. The patient had a 25Failure 7 (2005) 927–930d by Elsevier B.V.
Table 1
Composition of Xenadrin RFA-1 (Cytodyne Technologies, Lakewood, NJ)
Content in mg of two capsules of Xenadrin:
Citrus auranticum (4% synephrine), 125 mg
Ma Huang (6% ephedrine), 335 mg
Guarana extract (22% caffeine), 910 mg
White willow bark (15% salicin), 105 mg
Acetyl l-carnitine, 100 mg
l-Tyrosine, 80 mg
Ginger root, 50 mg
Vitamin B5, 40 mg
Xenadrin’s formula consists of ephedrine, caffeine, and salicin, all
chemicals which have been reported to have significant interactions.
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There was no history of illicit drug use.
Upon admission to the hospital, initial workup included a
blood toxicology screen, which was positive for cannabi-
noids. The cardiac markers were initially normal, but rose
significantly five h later (CK-MB was 112, normal b5; and
cardiac troponin I level was 33.1, normal 0.0–0.4), and
normalized after 5 days. The initial 12-lead electrocardio-
gram (ECG) on admission showed sinus tachycardia with
ST and T wave depressions in the anterior, lateral and
inferior leads, and Q waves in the inferior leads. A repeat
ECG 4 days later showed T wave inversions in the lateral
leads (leads I, AVL, V5-6). A CT scan of the brain showed
cerebral edema, but no haemorrhage or masses. A 2D
Echocardiogram revealed an ejection fraction of 25%, withFig. 1. Haematoxylin and eosin section of myocardium. (a) Myocytes containin
distribution. (b) Basophilic degeneration of a cardiac myocyte exhibiting a blue/gr
to myofibrillary loss. (d) Contraction bands within individual myocytes.global hypokinesis. The patient was subsequently admitted
to the Neuro ICU for further management. After 6 days on
life support, she was pronounced dead by electroencephalo-
gram, apnea test, and physical exam. Vasopressor support
(with Dopamine and Levophed to maintain a systolic blood
pressure above 95 mm Hg) was subsequently initiated for
organ preservation. The heart, which showed dilation of the
left ventricle with no evidence of coronary artery disease or
dissection, was explanted by the Organ Procurement Service
and preserved in cardioplegia solution for research pur-
poses. The cause of death was listed as respiratory failure
and cardiac arrest resulting in anoxic encephalopathy. The
causality assessment performed by means of the Naranjo
algorithm produced a score of 4, which categorized this
sudden cardiovascular event as a bpossibleQ adverse reaction
to ephedra.2. Laboratory assessments
Pathological evaluation revealed non-specific degener-
ative changes in the myocardium, including widespread
accumulation of lipofuscin pigment, basophilic degener-
ation and vacuolation of myocytes, following extensive
myofibrillary loss (Fig. 1). There was no evidence of
multifocal and confluent myocyte necrosis, myocarditis,
interstitial fibrosis, myocyte disarray, or myocyte hyper-
trophy, pathological features previously described ing lipofucsin pigment as brown granules with a predominantly perinuclear
ey amorphous material within the cytoplasm. (c) Myocyte vacuolization due
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ephedra intake [6]. However, evidence of acute ischemia
in the form of contraction band necrosis was also noted
(Fig. 1).
By immunohistochemistry, activation of caspase-9
(mitochondrial apoptotic pathway) and caspase-3 was
detected in the majority of cardiac cells (56F3.4% and
68F5.1%, respectively), although colocalization of
cleaved caspase-3 and TUNEL positive labelling, previ-
ously used as a marker of apoptotic cell death [7], was
only observed in a small number of myocytes (b5%) (Fig.
2a and b). Caspase-9 and caspase-3 activation was
confirmed both by Western blotting analysis and func-
tional evaluation of caspase activity, performed in tissue
extracts, as previously described (Fig. 2c) [8]. Conversely,
processing of caspase-8 (death receptor-mediated apop-
totic pathway) was never detected by any of the
aforementioned techniques (Fig. 2). In the same heart,
Western blot also documented cleavage of myofibrillary
proteins a-actin, a-actinin, and cardiac troponin T (cTnT),
with subsequent generation of cleaved fragments (Fig. 3).
Conversely, neither caspase activation, nor production of
a-actin, a-actinin, and cTnT fragments was observed in
three control hearts from subjects deceased from non-








Fig. 2. Low (panel a) and high (panel b) power field of cardiac myocytes showing
colocalized with TUNEL positive labeling (yellow/green nuclei). Caspase-3, -8 an
control hearts explanted from non-cardiac patients. Data are expressed as meanF3. Discussion
Ephedrine is a sympathomimetic drug (with both a-
and h-adrenergic agonist properties) whose cardiovascular
toxic effects are postulated to be due to several
mechanisms, including coronary artery vasoconstriction,
vasospasm, increase in cardiac contractility and automa-
ticity, shortening of the cardiac refractory periods (thereby
allowing development of re-entrant cardiac arrhythmias),
and myocardial ischemia, due to sudden increase in
myocardial oxygen requirements and catecholamine
excess, with resultant fibrosis and even death [1–4].
Lipofuscin, an end-product of intracellular lipid perox-
idation and a marker of cellular oxidative damage,
accumulates over time during the normal aging process
[9]. However, accelerated lipofuscin accumulation is asso-
ciated with numerous adverse effects [10].
Ephedra enhances norepinephrine release with subse-
quent catecholamine excess and increased sympathetic
output. The combination of ephedrine with caffeine (in
the form of guarana) and aspirin (in the form of white
willow bark or salicin) in the same over-the-counter
preparations, such as Xenadrin, is reported to markedly
potentiate the effects of ephedrine, by inducing sustained





cytoplasmic anti-active caspase-3 positive staining (bright red) sporadically
d -9 enzymatic activity (panel c) in tissue extracts from ephedra heart and
S.D. ***pb0.001 vs. control hearts.
Fig. 3. Western blotting showing reduction of intact a-actin (panel a), a-
actinin (panel b), and cardiac troponin T (cTnT; panel c), with subsequent
generation of smaller fragments, in the explanted ephedra heart, though not
in explanted hearts from patients deceased from non-cardiac reasons.
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setting of ephedra intake) leads to lipid peroxidation,
resulting in increased lipofuscin formation. In this setting,
malonaldehyde, a by-product, forms and reacts with
nuclear DNA, thereby blocking template activity and
reducing protein synthesis ability. As a consequence,
mitochondrial dysfunction and limitation in contractile
protein replacement occur [10].
Apoptosis has been implicated in the pathogenesis of
several cardiovascular disorders, including adrenergic-medi-
ated cardiac toxicity [11]. The apoptotic process is mediated
by specialised proteases, called caspases, whose sequential
activation is accountable for the cleavage of major cytosolic
and nuclear cell components [12]. Caspase activation has also
been associated with early myofibrillar protein cleavage,
resulting in decreased ATPase activity and contractile
dysfunction, before the occurrence of the typical DNA
fragmentation detected by TUNEL staining [11,13]. In
addition, h-adrenergic stimulation of isolated cardiac myo-
cytes was shown to induce early activation of caspase-9 and
caspase-3, via the mitochondria-initiated pathway, as well as
cleavage of cardiac troponin I and actin, when TUNEL
positive staining was not observed [13]. In line with these
findings, we observed broad myofibrillary loss, together with
extensive myocyte activation of caspase-9 and caspase-3,
which was largely independent from DNA fragmentation.
Since this pattern was not observed in previous studiescarried out in animal [7] and human [14] models of ischemia/
reperfusion injury, it is possible that ephedra toxicity, rather
than severe myocardial ischemia secondary to cardiac arrest,
is the predominant factor leading to massive caspase
activation mainly unrelated to DNA cleavage.
In conclusion, although the human data are necessarily
associative, and do not prove causation, our findings seem
to suggest that ephedra intake, via enhanced release of
sympathetic amines and following h-adrenergic stimulation,
may selectively trigger the mitochondria-initiated apoptotic
pathway, leading to caspase-9 and following caspase-3
activation. Upon activation, caspase-3 would induce early
breakdown of myofilaments, with subsequent functional
impairment of cardiac function, before the completion of the
apoptotic process, and independently from extensive
necrotic cell death. However, although this hypothesis is
well supported by experimental data in the rat, further
studies are needed to prove such a causative harmful effect
of ephedra in the human heart.References
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